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Background/Aims: The treatment with daclatasvir plus asu-
naprevir (DCV+ASV) is associated with potent antiviral effects 
in patients with genotype 1b hepatitis C virus (HCV) infec-
tion. We investigated the real-world efficacy, changes in liver 
stiffness and noninvasive fibrosis markers, and the safety 
of DCV+ASV treatment in Korean patients. Methods: In to-
tal, 363 patients with chronic hepatitis C were treated with 
DCV+ASV between August 2015 and January 2017. Finally, 
we analyzed the data of 270 patients who were monitored 
for at least 12 weeks after the end of treatment. Results: 
The mean age was 60.7 years, and females predominated 
(60.4%). Most patients (64.8%) were treatment-naïve, and 
56 patients (20.7%) had cirrhosis. Two hundred fifty-seven 
(95.2%) and 251 (93.0%) patients achieved end-of-treatment 
responses and sustained virological responses at 12 weeks 
posttreatment (SVR12), respectively. The SVR12 rates were 
higher in patients who were <65 years of age, males, without 
cirrhosis and had lower HCV RNA levels. All LS values and 
fibrosis-4 and aspartate aminotransferase-to-platelet ratio in-
dex values declined from baseline to the time of assessment 
of SVR12. Conclusions: The DCV+ASV therapy resulted in a 
high SVR12 and improved liver fibrosis; the treatment was 
well tolerated in patients with genotype 1b HCV infections. 
(Gut Liver 2018;12:324-330)
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INTRODUCTION
Approximately 180 million subjects are chronically infected 
with hepatitis C virus (HCV) worldwide.1,2 HCV infection is one 
of the leading causes of chronic liver disease, cirrhosis and he-
patocellular carcinoma (HCC).3,4 HCV is a single-stranded posi-
tive RNA virus with seven genotypes. Genotype 1b is the most 
predominant subtype in Asia, constituting 45% to 55% of all 
genotypes infecting patients in Korea and Taiwan.5,6 HCV treat-
ments have evolved rapidly with the development of direct-
acting antiviral (DAA) therapies. 
In HCV patients, DAA therapies are associated with higher 
sustained virological response (SVR) rates, reduced treatment 
durations, and minimal side-effects.7 DAAs target principally the 
HCV nonstructural protein (NS) 3/4A serine protease, the NS5A 
protein, and the NS5B polymerase.8 Daclatasvir (DCV; an NS5A 
replication complex inhibitor) plus asunaprevir (ASV; an NS3 
protease inhibitor) was recently approved in Korea as the first-
line DAA treatment for patients chronically infected by HCV 
genotype 1b.9,10 In a pooled analysis, a DCV+ASV regimen was 
effective and well-tolerated in patients with genotype 1b HCV 
infection, regardless of the presence of cirrhosis.11 However, 
real-world data often differ from those of clinical trials because 
clinical trials impose several strict inclusion and exclusion cri-
teria. Thus, the collection of real-life data is essential to confirm 
treatment efficacy and safety in clinical settings. 
DCV is a potent pan-genotypic NS5A inhibitor exhibiting 
antiviral activity across HCV genotypes 1 to 6 in vitro. ASV is 
an NS3 protease inhibitor active against genotypes 1, 4, 5, and 
6 in vitro.12 Dual therapy with DCV+ASV for 24 weeks, without 
the use of pegylated interferon/ribavirin (PegIFN/RBV), afforded 
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high SVR rates in treatment-naïve patients and those who were 
ineligible/intolerant (87%) or nonresponsive (81%) to PegIFN/
RBV treatment, provided that they lacked resistance-associated 
substitutions (RAS).13-15 Moreover, DCV+ASV treatment was 
associated with favorable SVR rates and low levels of adverse 
events, even in patients with compensated cirrhosis.16,17
Viral eradication with IFN-treatment of chronic hepatitis C 
(CHC) liver fibrosis and reduces the incidences of HCC and liver-
related mortality. However, any long-term benefit afforded by 
viral eradication in HCV-infected patients using IFN-free DAA 
combination therapy, remains unknown.18-20 A recent study 
founded that improvement of fibrosis was important in CHC 
patients who treated with sofosbuvir-based regimen.21 Although 
the efficacy and changes in fibrosis have been assessed in clini-
cal trials, few real-world data are available.17,22 Therefore, we 
investigated the real-world efficacy, changes in liver stiffness (LS) 
values and the fibrosis markers, and safety in Korean patients 
with genotype 1b HCV infection. 
MATERIALS AND METHODS
1. Patients 
A total of 363 patients chronically infected with HCV geno-
type 1b started 24 weeks treatment with DCV+ASV at Sever-
ance Hospital, Yonsei University College of Medicine, Seoul, 
Korea between August 2015 and January 2017. The doses were 
DCV 60 mg once daily and ASV 100 mg twice daily. All data 
were prospectively collected using an established protocol and 
were followed up for 12 weeks posttreatment.
The inclusion criteria were age 20 years, CHC infection with 
genotype 1b only, and a detectable HCV RNA titer without any 
RAS (Fig. 1). Patients who were nonresponsive to, ineligible for, 
or intolerant of previous treatment, and those who had relapsed, 
were included. The exclusion criteria were: (1) hepatic decom-
pensation evident at the time of enrollment or a prior history of 
decompensation; (2) co-infection with other HCV genotypes or 
hepatitis B virus; (3) RAS positive at L31 or Y93 (n=36); (4) HCC 
evident at enrollment (n=53); and (5) loss to follow-up (n=4). 
Our analyses of efficacy and safety included all patients who 
received at least one dose of medication. 
Written informed consent was obtained from all participants. 
The study was approved by the Institutional Review Board of 
Severance Hospital and conformed to the ethical guidelines of 
the 1975 Helsinki Declaration (IRB Number: 4-2015-0701).
2. Clinical and laboratory evaluation
The RASs in the HCV NS5A and HCV NS3 regions were ana-
lyzed by Sanger direct-sequencing methods. Clinical data in-
cluding age, sex, HCV genotype, HCV RNA titer, comorbidities, 
prior HCV treatment history, and the presence of cirrhosis was 
assessed at baseline. Clinical assessment was performed at weeks 
4, 12, 24 and 36. At each visit, a complete blood cell count, rou-
tine blood chemistry tests, and side effects were checked. HCV 
RNA level were checked at baseline; at 4, 12, and 24 weeks of 
treatment; and at 12 weeks after the end of treatment (EOT). 
Serum HCV RNA levels were quantified using a commercial 
polymerase chain reaction assay (Amplicor HCV; Roche Diag-
nostics, Seoul, Korea), which has a lower limit of quantification 
of 15 IU/mL. Serum alanine aminotransferase (ALT) levels were 
measured using a standard laboratory procedure with the up-
per limit of normal set to 33 IU/mL in males and 25 IU/mL in 
females.23 During the follow-up period, all patients underwent 
periodic ultrasonographic and laboratory work-ups, including 
measurement of -fetoprotein levels every 3 or 6 months to 
screen for HCC and other portal hypertension-related complica-
tions. 
Cirrhosis was diagnosed by liver biopsy (METAVIR score 4 or 
Ishak score 5, 6), by transient elastography (TE) (LS value >12.5 
kilopascal [kPa]), or by measurement of laboratory biomarkers 
(aspartate aminotransferase to platelet ratio index [APRI] >2.0 
and fibrosis-4 [FIB-4] score >3.25.24,25
3. Changes in fibrosis assessed by noninvasive markers
To assess the effect of DCV+ASV treatment, liver fibrosis 
markers, including the APRI and FIB-4 scores, were measured 
in all patients at baseline, at the EOT, and at 12 weeks after 
treatment. An APRI >2.0 predicts cirrhosis and a FIB-4 >3.25 
predicts advanced fibrosis with a positive predictive value of 
65%.26,27 LS values were assessed by TE both at baseline and 
SVR12. TE examinations were performed by a single experi-
270 Patients were finally analyzed
History of hepatic decompensation
Co-infection with other HCV genotypes or HBV
RAS positive at L31 or Y93
HCC at enrollment
Loss to follow-up loss
363 Patients with HCV genotype 1b
infection receiving daclatasvir plus
asunaprevir
Fig. 1. Recruitment algorithm. 
HCV, hepatitis C virus; HBV, hepati-
tis B virus; RAS, resistance-associat-
ed substitutions; HCC, hepatocellular 
carcinoma. 
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enced technician (>20,000 examinations) blinded to patient 
data. The results were expressed in kilopascal and the median 
value of successful measurements was selected as representa-
tive LS value. The interquartile range (IQR) was defined as an 
index of the intrinsic variability of LS values corresponding to 
the interval of LS results containing 50% of the valid measure-
ments between the 25th and 75th percentiles. Only LS values 
derived from 10 valid shots, a success rate 60%, and an IQR 
to median value ratio <0.3 were considered reliable, and used in 
statistical analysis.28
4. Assessment of treatment efficacy and safety
The primary endpoint was to evaluate SVR12, defined as 
undetectable HCV RNA at 12 weeks posttreatment. The second 
endpoint was to evaluate the changes in liver fibrosis assessed 
by noninvasive methods before and after DCV+ASV treatment. 
Treatment responses were defined as follows: relapse; an end of 
treatment response (ETR), defined as undetectable HCV RNA at 
the end of treatment; virological breakthrough (VBT); ALT nor-
malization. Adverse events were assessed at each visit.
5. Statistical analysis
Data are expressed as mean±standard deviation (SD), median 
(with range), or numbers (with percentages), as appropriate. 
Continuous and categorical variables were compared using Stu-
dent t-test (or the Mann-Whitney U-test, as appropriate); and 
the chi-square test (or Fisher exact test, as appropriate), respec-
tively. All statistical analyses were performed using SPSS ver-
sion 20.0 (IBM Corp., Armonk, NY, USA). A p-value <0.05 was 
considered statistically significant.
RESULTS
1. Baseline characteristics 
A total of 270 patients followed up for at least 12 weeks after 
treatment were finally analyzed. Their baseline demographic 
characteristics are summarized in Table 1. The mean patient age 
was 60.7 years (SD, 12.4 years), and females (n=163, 60.4%) 
predominant. Treatment-naïve patients (n=175, 64.8%) were in 
the majority. The mean baseline HCV RNA level was 5.9 log10 
Table 1. Baseline Characteristics of the Study Population (n=270)
Variable Value
Age, yr 60.7±12.4
    <65 156 (57.8)
    65 114 (42.2)
Female sex 163 (60.4)
Cirrhosis  56 (20.7)
Body mass index, kg/m2 23.5±3.2
Prior HCV therapy
    Treatment-naïve 175 (64.8)
    Non-responders 37 (13.7)
    IFN/RBV ineligible/intolerant 31 (11.5)
    Relapsers 27 (10.0)
HCV RNA, log10 IU/mL 5.9±0.9
Aspartate aminotransferase, IU/L 54.3±39.1
Alanine aminotransferase, IU/L 46.6±39.1
Platelet count, 103/L 164.8±65.4
Total cholesterol, mg/dL 167.3±31.3
-Fetoprotein , ng/mL 5.9±0.8
Liver stiffness values, kPa 13.2±12.6
CAP, dB/m 228.6±38.1
APRI score 1.13±1.25
FIB-4 score 4.39±4.66
Data are presented as mean±SD or number (%). 
HCV, hepatitis C virus; IFN, interferon; RBV, ribavirin; CAP, con-
trolled attenuation parameter; APRI, aspartate aminotransferase to 
platelet ratio index; FIB-4, fibrosis-4.
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IU/mL (SD, 0.9 log10 IU/mL). Of all patients, 56 (20.7%) had cir-
rhosis. The mean LS value was 13.2 kPa (SD, 12.6 kPa) at base-
line. 
2. Virological response
Of all patients, 214 patients (79.3%) achieved rapid viro-
logic response defined as undetectable HCV RNA at week 4 
of therapy. Two hundred fifty-seven (95.2%) and 251 (93.0%) 
patients achieved ETR and SVR12, respectively (Fig. 2A). The 
SVR12 rates by prior treatment history were 92.0% (161/175) 
in treatment-naïve patients and 94.7% (90/95) in those with 
treatment-experienced (35/37 in non-responders, 30/31 in IFN/
RBV ineligible/intolerant patients, and 25/27 in relapsers) (Fig. 
2B). The SVR12 rates were higher in patients <65 years than 
in those 65 years of age (91.9%, 136/148 vs 90.4%, 103/114) 
(Fig. 3). The SVR rate was higher in males (94.4%, 101/107) 
than females (92.0%, 150/163). SVR12 was achieved both in 
patients with cirrhosis (87.5%, 49/56) and those without cirrho-
sis (94.4%, 202/214). When subdivided by the HBV RNA level, 
95.2% (119/125) of patients with levels 6 log10 IU/mL and 
91.0% (132/145) of patients with levels <6 log10 IU/mL achieved 
SVR12. The SVR rate was 92.3% (12/13) in patients with esti-
mated glomerular filtration rates (eGFR) <50 mL/min/1.73m2 
and 93.0% (239/257) in those with eGFR 50 mL/min/1.73m2. 
In patients with and without diabetes mellitus, 93.5% (29/31) 
and 92.9% (222/239) of patients achieved SVR12, respectively.
3. Safety and virological failure
Of patients who had no HCC at baseline and were RAS nega-
tive, 16 patients discontinued DCV+ASV treatment prior to 
24 weeks because of the development of adverse events (n=5), 
treatment failure (n=3), and VBT (n=8). One patient discontin-
ued DCV+ASV treatment at week 2 because of gastrointestinal 
problem. Another developed a skin rash and stopped treatment 
at week 12. One 63-year-old female patient exhibited mild cre-
atinine elevation (from 1.3 to 2.3 mg/dL at week 4) and refused 
to continue treatment. One 71-year-old female patient stopped 
treatment at week 4 because of general weakness. One patient 
discontinued treatment because of uncontrolled ascites at week 
20. Among five patients who experienced adverse events, four 
(80%) had cirrhosis at baseline. Three patients experienced ETR, 
but recurred at 12 weeks after treatment completion.
DCV+ASV treatment was relatively safe, but one patient 
experienced drug-drug interactions. She visited the hospital at 
24 weeks and we confirmed ETR. However, she was admitted 
for treatment of severe hepatitis (ALT >5-fold the upper limit 
of normal), even though her HCV RNA status was negative. 
The hepatitis was caused by itraconazole for treatment 1 week 
in duration; the drug had been prescribed in another clinic to 
treat vaginitis. After conservative care, she was discharged with 
improved liver enzyme levels and achieved both an ETR and 
SVR12. Two patients who achieved SVR12 developed HCC. Both 
had cirrhosis at baseline and developed HCC approximately 3 
months after the end of treatment. 
4. Changes in liver fibrosis 
The LS values obtained by TE, showed that 49.0% of pa-
tients had non-significant fibrosis (grade <F2), 10.2% mild to 
Table 2.  Changes in Noninvasive Fibrosis Markers at Baseline and SVR12
No. of 
patients
Liver stiffness values FIB-4 APRI
Baseline SVR12 p-value Baseline SVR12 p-value Baseline SVR12 p-value
Total 270 (100) 13.2±12.8 10.5±8.8 4.57±4.78 3.03±3.08 1.40±1.36 0.60±0.54
Cirrhosis 56 (20.7) 25.5±17.5 19.8±11.4 <0.001 8.76±6.23 5.19±4.98 <0.001 2.39±1.10 1.13±0.70 <0.001
No cirrhosis 214 (79.3) 8.6±6.0 6.7±3.2 <0.001 2.87±2.55 2.34±1.66 0.001 0.97±1.23 0.38±0.23 <0.001
Treatment naïve 175 (64.8) 9.9±8.3 7.7±4.7 0.001 3.49±3.21 2.41±1.59 <0.001 1.05±0.86 0.49±0.38 <0.001
Treatment experienced  95 (35.2) 17.9±16.4 14.1±11.3 <0.001 6.24±6.16 3.98±4.34 0.003 1.91±1.75 0.76±0.70 <0.001
Data are presented as number (%) or mean±SD.
SVR, sustained virological response; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.
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significant fibrosis (F2–F3), 10.2% advanced fibrosis (F3–F4) 
and 30.6% cirrhosis (F4). The FIB-4 score was 4.39±4.66 and 
the mean APRI 1.13±1.30. All patients exhibited declines in the 
levels of noninvasive fibrosis markers at SVR12 compared with 
baseline. Significant decline were also evident in the LS, FIB-4, 
and APRI values from baseline to SVR12 regardless of cirrhosis 
status or any prior history of treatment (Table 2). The overall LS 
values by TE decreased significantly from 13.2 kPa at baseline 
to 10.5 kPa at SVR12 (p<0.001). The overall APRI and FIB-
4 scores also decreased significantly (Fig. 4). The mean APRI 
score prior to therapy was 1.40 and that after therapy was 0.60 
(p<0.001). The mean FIB-4 value was 4.57 prior to treatment 
and 3.03 at 12 weeks posttreatment.
DISCUSSION
We investigated the real-world efficacy of DCV+ASV treat-
ment in patients infected with genotype 1b HCV. DCV+ASV 
treatment was approved in 2015; and our center has treated 
the greatest number of patients and has the most extensive col-
lection of long-term data as a single institution in Korea. HCV 
infection is the second most common cause of chronic liver dis-
ease in Korea. HCV prevalence is especially highest among older 
patients, with rapid disease progression. Of all HCV patients, 2% 
were 70 years of age, and were predominantly female. HCV 
genotype 1b is the most prevalent subtype in Korea; the preva-
lence ranges from 45 % to 59 %.29,30 
ETR was achieved in 95.2% and SVR12 was achieved in 
93.0% of all patients. Thus, Korean patients with HCV genotype 
1b responded well to treatment regardless of age, sex, cirrhosis 
status, or HCV RNA levels. In previous studies, DCV+ASV treat-
ment was associated with SVR12 in 90% of treatment-naïve pa-
tients, 82% of non-responders, and 82% of ineligible/intolerant 
patients.11 Our results were similar; 92.0% of treatment-naïve 
patients achieved SVR12. Ninety-four point six percent (35/37) 
patients of non-responders, 96.0% (30/31) of ineligible/intoler-
ant patients, and 92.6% (25/27) patients of relapsers showed 
SVR12.
We treated 36 (9.9%, 36/363) patients with NS5A-Y93 (n=28) 
mutations and/or NS5A-L31 mutations (n=9). Nineteen patients 
(52.8%) achieved SVR12. Three patients exhibited VBT and two 
were non-responders. The SVR rate of RAS-positive patients 
was slightly higher than that observed in previous clinical tri-
als. We sequenced the viral genomes of five patients who failed 
DCV+ASV treatment. The well-known Y93H mutation of NS5A 
was observed in four. Substitution mutations at Leu31 (Val or 
Met) of NS5A were also observed in three out of the four Y93H-
containing viruses. However, one genome had no substitution 
mutation at Leu31 and Tyr93 having, rather, a deletion muta-
tion at Pro32. 
Overall, 87.5% of cirrhotic patients achieved SVR12 (87.5% 
in cirrhosis vs 94.4% in non-cirrhosis, p=0.908). This low treat-
ment outcome is probably due to the low number of patients 
with cirrhosis (n=56) compared with non-cirrhosis (n=214), so 
a larger number of cirrhotic patients is needed. The concentra-
tion of ASV after treatment commencement is associated with 
a higher rate of ALT elevation in patients with cirrhosis.31 How-
ever, none of our patients discontinued treatment because the 
ALT level raised to 5-fold that of the normal upper limit. Of 53 
patients with HCC at baseline, 54.7% (29/53) achieved SVR12. 
Seven HCC patients ceased treatment because of loss to follow-
up, the development of adverse events, or the absence of any 
response. Three died of HCC progression. DCV+ASV have been 
reported to be relatively safe even in patients with compensated 
cirrhosis and/or HCC.
DCV+ASV can be safely prescribed for patients with mild-
to-moderate renal impairment; dose adjustments are not neces-
sary.32 However, few data are available on whether doses should 
be adjusted for patients with severe renal impairment/end-stage 
renal disease. We found that 92.3% of patients with eGFR <50 
mL/min/1.73m2 achieved SVR12. One patient with chronic kid-
ney disease voluntarily discontinued treatment. 
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Current treatment goals for HCV patients focus on viral eradi-
cation; however, improvement of fibrosis is also important in 
patients treated with DAAs.21 Thus, serial estimation of fibrosis 
status is required to predict treatment response and prognosis. 
Liver biopsy is an imperfect gold standard; being prone to inter-
observational variation in pathologists’ reports; also, the tissue 
samples obtained may not be representative of the entire liver. 
Thus, the use of noninvasive markers of fibrosis to follow-up 
patient treated with DAAs is considered. Previous report has 
shown that the LS value at the time of SVR usefully predicted 
liver-related events in CHC patients treated with pegIFN/RBV.33 
Thus, noninvasive markers should be evaluated and considered 
to incorporate as surveillance protocols.34 However, a reduction 
of LS value did not always correlated with the improvement of 
portal hypertension.35 Thus, HVPG should be monitored together 
with the changes of LS value.
Our study had several limitations. First, the study was ret-
rospective, so data collection was not as strict as mandated in 
clinical trials. However, we collected all data prospectively using 
a unified in-house protocol. Second, we did not perform liver 
biopsy (this is the gold standard for assessment of fibrosis re-
gression). It is ethically difficult to perform serial liver biopsies. 
Thus, we have no pathologic confirmation of our assessments of 
liver fibrosis. Thus, the exact mechanism such as the improve-
ment of fibrosis or inflammation was hard to be confirmed. 
However, recent studies showed that LS values compared with 
FIB4/APRI was fairly reliable to predict fibrosis and treatment 
response in patients with chronic viral hepatitis.36,37 Further 
long-term follow-up data are needed. Lastly, for patients who 
have failed DCV+ASV treatment, the following treatment regi-
men has yet to set guidelines and is waiting for other new 
drugs.
In conclusion, DCV+ASV treatment was generally well toler-
ated in real-world clinical practice, with few discontinuations 
caused by the development of adverse events. Patients with CHC 
exhibited virological responses similar to those noted in clinical 
trials; and safety profile was also similar. 
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